The drug budget for the next year is not sufficient to meet the country’s needs.
Mohammad Abdohzadeh, the Chairman of the Syndicate of Iran’s Human Pharmaceutical Industries, states that the proposed budget by the Food and Drug Organization, which is 105 trillion tomans, should be provided instead of the planned budget of 69 trillion tomans. If this difference is not covered, it will create two situations: either the insurance fulfills its commitments but reduces the coverage and puts the financial burden on the companies and drug suppliers, or the insurance is forced to exclude certain drugs from coverage, reducing its commitments to the people. Therefore, the cost of obtaining medication will fall on the people, and ultimately, it will be seen negatively by the public.
